Attached files

file filename
10-K - KERYX BIOPHARMACEUTICALS INCv178368_10k.htm
EX-23.2 - KERYX BIOPHARMACEUTICALS INCv178368_ex23-2.htm
EX-21.1 - KERYX BIOPHARMACEUTICALS INCv178368_ex21-1.htm
EX-32.1 - KERYX BIOPHARMACEUTICALS INCv178368_ex32-1.htm
EX-31.1 - KERYX BIOPHARMACEUTICALS INCv178368_ex31-1.htm
EX-23.1 - KERYX BIOPHARMACEUTICALS INCv178368_ex23-1.htm
EX-31.2 - KERYX BIOPHARMACEUTICALS INCv178368_ex31-2.htm

Exhibit 32.2

STATEMENT OF CHIEF FINANCIAL OFFICER OF
KERYX BIOPHARMACEUTICALS, INC.
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION  906 OF THE SARBANES-OXLEY ACT OF 2002

        In connection with the annual report of Keryx Biopharmaceuticals, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2009 as filed with the Securities and Exchange Commission (the “Report”), I, James F. Oliviero, Chief Financial Officer, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:
 
1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: March 25, 2010
/s/ James F. Oliviero                          
 
James F. Oliviero
Chief Financial Officer
Principal Financial and Accounting Officer